Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Aurel Perren"'
Autor:
Eva Karamitopoulou, Aurélie Pahud de Mortanges, Aurel Perren, Beat Gloor, Andreas Andreou, Marianne Tinguely
Publikováno v:
Cancer Immunology Research. 9:1439-1450
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluor
Autor:
Emanuel Christ, François Pattou, Beat Gloor, Aurel Perren, Damian Wild, Jean Claude Reubi, Ashley B. Grossman, Deborah R. Vogt, Philippe Chanson, Kwadwo Antwi, Tobias Heye, Melpomeni Fani, Guillaume Nicolas
Publikováno v:
Antwi, Kwadwo; Nicolas, Guillaume; Fani, Melpomeni; Heye, Tobias; Pattou, Francois; Grossman, Ashley; Chanson, Philippe; Reubi, Jean Claude; Perren, Aurel; Gloor, Beat; Vogt, Deborah R; Wild, Damian; Christ, Emanuel (2019). 68Ga-exendin-4 PET/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1. The journal of clinical endocrinology and metabolism, 104(12), pp. 5843-5852. Oxford University Press 10.1210/jc.2018-02754
Context Surgical intervention is advised in patients with multiple endocrine neoplasia type-1 (MEN-1) and nonfunctioning pancreatic neuroendocrine tumors (PanNETs) with a size ≥20 mm. Functioning PanNETs, such as in patients with endogenous hyperin
Autor:
Roch-Philippe Charles, Marc-David Ruepp, Matthias A. Roelli, Stefan Forster, Philippe Krebs, Renaud Maire, Frido Brühl, Matthias S. Dettmer, Sergio Di Pancrazio, Roland Giger, Marie-Hélène Wasmer, Aurel Perren, Anja Schmitt, Christian M. Schürch
Publikováno v:
Schürch, C M, Roelli, M A, Forster, S, Wasmer, M-H, Brühl, F, Maire, R, Di Pancrazio, S, Ruepp, M-D, Giger, R, Perren, A, Schmitt, A, Krebs, P, Charles, R-P & Dettmer, M S 2019, ' Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy ', Thyroid, vol. 29, no. 7, pp. 979-992 . https://doi.org/10.1089/thy.2018.0555
Schürch, Christian M; Rölli, Matthias A.; Forster, Stefan; Wasmer, Marie-Hélène; Brühl, Frido; Maire, Renaud S.; Di Pancrazio, Sergio; Ruepp, Marc-David; Giger, Roland; Perren, Aurel; Schmitt, Anja M.; Krebs, Philippe; Charles, Roch-Philippe; Dettmer, Matthias S. (2019). Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Thyroid, 29(7), pp. 979-992. Mary Ann Liebert 10.1089/thy.2018.0555
Thyroid
Schürch, Christian M; Rölli, Matthias A.; Forster, Stefan; Wasmer, Marie-Hélène; Brühl, Frido; Maire, Renaud S.; Di Pancrazio, Sergio; Ruepp, Marc-David; Giger, Roland; Perren, Aurel; Schmitt, Anja M.; Krebs, Philippe; Charles, Roch-Philippe; Dettmer, Matthias S. (2019). Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Thyroid, 29(7), pp. 979-992. Mary Ann Liebert 10.1089/thy.2018.0555
Thyroid
Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers, with a median survival of only three to six months. Standard treatment options and even targeted therapies have so far failed to improve long-term overall sur
Autor:
Christopher B. Nahm, Veronica K. Y. Cheung, Anthony J. Gill, Angela Chou, Jaswinder S. Samra, Jennifer Arena, Aurel Perren, Loretta Sioson, Philip R. de Reuver, Malinda Itchins, Marina Pajic, Adele Clarkson, Anubhav Mittal, Amy Sheen
Publikováno v:
Chou, Angela; Itchins, Malinda; de Reuver, Philip R; BSc, Jennifer Arena; BSc, Adele Clarkson; BSc, Amy Sheen; BSc, Loretta Sioson; MChD, Veronica Cheung; Perren, Aurel; Nahm, Christopher; Mittal, Anubhav; Samra, Jaswinder S; Pajic, Marina; Gill, Anthony J (2018). ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumours. Human pathology, 82, pp. 249-257. Elsevier 10.1016/j.humpath.2018.07.032
Human Pathology, 82, pp. 249-257
Human Pathology, 82, 249-257
Human Pathology, 82, pp. 249-257
Human Pathology, 82, 249-257
Item does not contain fulltext Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounting for 1% to 2% of all pancreatic tumors. The biological behavior of PanNETs is heterogeneous and unpredictable, adding to the difficulties of clinic
Autor:
Oskar Koperek, Bruno Niederle, Reto Kaderli, Aurel Perren, Andreas Selberherr, Philipp Riss, Christian Scheuba
Publikováno v:
Selberherr, Andreas; Koperek, Oskar; Riss, Philipp; Scheuba, Christian; Kaderli, Reto; Perren, Aurel; Niederle, Bruno (2019). Neuroendocrine Liver Metastasis-a Specific Set of Markers to Detect Primary Tumor Sites. Endocrine pathology, 30(1), pp. 31-34. Springer 10.1007/s12022-018-9558-z
The diagnosis of neuroendocrine neoplasia (NEN) is often made at an advanced stage of disease, including hepatic metastasis. At this point, the primary may still be unknown and sometimes cannot even be detected by functional imaging, especially in ve
Autor:
Abir Salwa Ali, Aurel Perren, Cecilia Lindskog, Staffan Welin, Halfdan Sorbye, Malin Grönberg, Eva Tiensuu Janson
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumours that compose 1–2% of all pancreatic tumours. Patients with metastatic grade 3 neoplasia are usually treated with chemotherapy but have a poor progression-free and overall survival. Acco
Autor:
Lorenza Pecciarini, Greta Grassini, Claudio Doglioni, Renaud Maire, Marco Schiavo Lena, Aurel Perren, Maria Giulia Cangi, Ilaria Francaviglia, Massimo Falconi, Stefano Partelli
Recently, the term mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) has been proposed as an umbrella definition covering different possible combinations of mixed neuroendocrine-exocrine neoplasms. Among these, the adenoma plus neuroendocrine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb33a822c608353fcda23bb9f7854668
Autor:
Owen W J, Prall, Violeta, Nastevski, Huiling, Xu, Christopher R E, McEvoy, Joep H A, Vissers, David J, Byrne, Elena, Takano, Satwica, Yerneni, Sarah, Ellis, Thomas, Green, Catherine A, Mitchell, William K, Murray, Clare L, Scott, Sean M, Grimmond, Oliver, Hofmann, Anthony, Papenfuss, Damien, Kee, Andrew, Fellowes, Ian S, Brown, Gregory, Miller, M Priyanthi, Kumarasinghe, Aurel, Perren, Christopher B, Nahm, Anubhav, Mittal, Jaswinder, Samra, Mahsa, Ahadi, Stephen B, Fox, Angela, Chou, Anthony J, Gill
There is now evidence that gene fusions activating the MAPK pathway are relatively common in pancreatic acinar cell carcinoma with potentially actionable BRAF or RET fusions being found in ~30%. We sought to investigate the incidence of RAF1 fusions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fd90221d40da6dd6ec181cd7fb90de
Autor:
Valentina Andreasi, Attila Kollár, Birgit Cremer, Francesco Panzuto, Daniel Kaemmerer, Henning Jann, Anja Rinke, Aurel Perren, Abbas Agaimy, Massimo Falconi, Elettra Merola, Rainer W. Lipp, Emanuel Christ, Patrizia Kump, Ruza Arsenic, Stefano Partelli, Thomas M. Gress, Marianne Pavel, Bertram Wiedenmann, Andreas Pascher
Background: While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a56dd895fdc71b72d7a1a2e26cd9227d
Autor:
Maria Chiara Zatelli, Corrado Rubini, Andrea Doria, Carmelina Di Pasquale, Massimo Falconi, Aurel Perren, Ilaria Marinoni, Stefano Partelli, Dominik Nann, Vanessa Polenta, Ettore C. degli Uberti, Simona Falletta
Publikováno v:
Endocrine-Related Cancer. 23:883-891
Medical therapy of pancreatic neuroendocrine tumors (P-NET) may take advantage of Everolimus treatment. However, the extent of therapeutic response cannot be predicted. This study was aimed to identify the possible predictive markers of response to E